Zacks Investment Research on MSN4d
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)Corbus Pharmaceuticals (CRBP) has been on a downward spiral lately with significant selling pressure. After declining 22.9% ...
This was the stock's second consecutive day of losses.
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at ...
NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...
Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus ...
During the fourth quarter and into 2025, we made significant progress across our pipeline. Both of our oncology programs have been advancing ...
The stock's fall snapped a two-day winning streak.
CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western studyFast Track Designation granted by FDA for CRB-701 to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback